Cory Kazimov

Senior Managing Director and fundamental research analyst at Evercore Wealth Management, LLC

Cory Kasimov is a Senior Managing Director and fundamental research analyst at Evercore ISI, where he leads coverage of small- and mid-cap biotech companies with a strong track record recognized by top industry publications. He covers dozens of notable biotech firms including Moderna, BioCryst, Editas Medicine, and Clovis Oncology, and has delivered an average return of 17.6% per rating with a 55% success rate and a top ranking (#243 of 9,946) among Wall Street analysts. Kasimov began his career in healthcare research at Oppenheimer in 2003, spent over 15 years as a senior biotech analyst at JPMorgan, and joined Evercore ISI as Senior Managing Director in November 2023. He holds an MBA and MPH from Tulane University, a B.S. in cellular and molecular biology from Tulane, and is consistently recognized in Institutional Investor’s All-America Research poll for his biotech coverage.